Advair HFA (salmeterol xinafoate/fluticasone propionate inhalation aerosol) / GSK - LARVOL DELTA

Projected Savings on Inhalers Purchased Via Mark Cuban Cost Plus Drug Company (MCCPDC) Versus Medicare Part-D (ATS 2024) - "Top Pulmonology inhalers studied were Albuterol Sulfate (Ventolin), Albuterol Sulfate (Proair), Albuterol sulfate (Proventil), Albuterol Sulfate HFA, Fluticasone Salmeterol (Advair Diskus) and Fluticasone Salmeterol (Advair HFA). Purchasing prescription drugs through MCCPDC showed substantial potential cost-savings for pulmonology directed rugs. MCCPDC could be a reasonable financial alternative for Medicare Part D spending on pulmonology drugs to reduce the financial burden of healthcare related costs."

Medicare • Reimbursement • US reimbursement • Alpha-1 Antitrypsin Deficiency • Chronic Obstructive Pulmonary Disease • Critical care • Genetic Disorders • Immunology • Pulmonary Disease • Respiratory Diseases

Warren rebukes GSK for alleged 'money grab' after company pulled popular asthma med (Fierce Pharma) - "After removing Flovent HFA from the market, GSK and its partner substituted an authorized generic version with a lower list price—currently around $310—compared to the branded product’s $340...The spokesperson explained that GSK elected to launch authorized generics for Flovent HFA and its sister product Flovent Diskus to help maintain patient access to the drug, potentially at a lower cost...GSK in December removed four patents related to its inhaler products Advair, Annuity, Flovent and Ventolin from the FDA’s Orange Book following the U.S. Federal Trade Commission’s (FTC’s) recent crackdown on 'improper' listings."

Discontinued • Patent • Pricing • Asthma

SWIFTARC: Advair HFA in Healthy and HAPE Predisposed Subjects (clinicaltrials.gov) - P1/2 | N=60 | Recruiting | Sponsor: University of Colorado, Denver | Not yet recruiting ➔ Recruiting

Enrollment open • Respiratory Diseases

SWIFTARC: Advair HFA in Healthy and HAPE Predisposed Subjects (clinicaltrials.gov) - P1/2 | N=60 | Not yet recruiting | Sponsor: University of Colorado, Denver

New P1/2 trial • Respiratory Diseases

Corticosteroid-LABA inhalers increase phonation threshold pressure (PTP) and flow (PTF) in rabbits. (PubMed, Laryngoscope) - "Following 8-week exposure to ICs, rabbit larynges required greater air pressure and flow to initiate phonation. Because even modest phonation onset differences can have a meaningful clinical impact on voice function, these findings suggest that LABA ICs may put patients at risk for voice disorders. Furthermore, these voice disorders may occur within a relatively short timeframe. The results from this study have important clinical implications for voice care in those who use ICs."

Journal • Preclinical • Otorhinolaryngology

ARGARG: Evaluating Long Acting Beta Agonists Used to Treat Asthma Among Those With Either Arg/Arg or Gly/Gly Genotypes (clinicaltrials.gov) - P=N/A | N=89 | Completed | Sponsor: Columbia University | Unknown status ➔ Completed

Trial completion • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases

Bioequivalence Study of Fluticasone Propionate 250 mcg and Salmeterol Xinafoate 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 250/50 Inhalation Powder/GSK in Healthy Volunteers (clinicaltrials.gov) - P1; N=18; Active, not recruiting; Sponsor: Respirent Pharmaceuticals Co Ltd.

Clinical • New P1 trial • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases

Uncontrolled Lower Respiratory Symptoms in the WTC Survivor Program (clinicaltrials.gov) - P=N/A; N=60; Completed; Sponsor: NYU Langone Health; N=94 ➔ 60

Enrollment change • Respiratory Diseases

"@GSKUS Can you bring back the coupon for the Advair HFA inhaler? I have no insurance and can’t use the diskus (it makes my symptoms worse). @GoodRx" (@Hubbyboogie)

Reimbursement

Uncontrolled Lower Respiratory Symptoms in the WTC Survivor Program (clinicaltrials.gov) - P=N/A; N=94; Completed; Sponsor: NYU Langone Health; Active, not recruiting ➔ Completed

Trial completion • POSTN